Dave Savastano08.07.14
Gentag, Inc. announced that it has been granted additional allowances for its patents in Europe, which will greatly enhance the company’s already significant intellectual property holdings of near field communication (NFC) sensor technologies related to wearable biosensors, body-area-networks (BAN), sensor diagnostics and advanced geolocation.
Gentag’s patents address the uses of disposable diagnostic NFC devices, including skin patches and associated readers in cell phones, and will issue in 30 countries, including Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Germany, Estonia, Finland, France, Greece, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Monaco, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, Spain, Switzerland, Turkey and the United Kingdom.
With the Gentag technology, it becomes possible to integrate ultrathin battery-less wireless sensors into disposable skin patches for medical and consumer market applications such as fever monitoring, painless diabetes monitoring, drug delivery and obesity monitoring. Gentag’s core suite of patented technologies covers advanced geolocation; environmental genomics, including NFC immunoassays; NFC diagnostic skin patches; and BAN sensor networks. Its first wearables patent was filed in 1997.
Gentag’s patents address the uses of disposable diagnostic NFC devices, including skin patches and associated readers in cell phones, and will issue in 30 countries, including Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Germany, Estonia, Finland, France, Greece, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Monaco, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, Spain, Switzerland, Turkey and the United Kingdom.
With the Gentag technology, it becomes possible to integrate ultrathin battery-less wireless sensors into disposable skin patches for medical and consumer market applications such as fever monitoring, painless diabetes monitoring, drug delivery and obesity monitoring. Gentag’s core suite of patented technologies covers advanced geolocation; environmental genomics, including NFC immunoassays; NFC diagnostic skin patches; and BAN sensor networks. Its first wearables patent was filed in 1997.